Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson's Disease-affected Patients

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 7, 2021

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions

Parkinson Disease

Interventions

DRUG

Talineuren

Talineuren is a liposomal formulation of the GM1 Ganglioside for intravenous administration

Trial Locations (1)

Neurologisches Institut Konolfingen, Konolfingen

All Listed Sponsors

lead

InnoMedica Schweiz AG

INDUSTRY